Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?

Ann Transl Med. 2018 May;6(10):192. doi: 10.21037/atm.2018.03.19.

Authors

Muhammad Abdul-Ghani¹, Amin Jayyous¹, Nidal Asaad², Sherif Helmy², Jassim Al-Suwaidi²

Affiliations

¹ Academic Health System, Hamad General Hospital, Doha, Qatar.
² Cardio-Metabolic Institute, Hamad General Hospital, Doha, Qatar.

No abstract available

Publication types

Editorial
Comment